Page 382 - Read Online

Marasco et al. Hepatoma Res 2020;6:33 I http://dx.doi.org/10.20517/2394-5079.2020.01 Page 17 of 19

136. Liao X, Yi J, Li X, Yang Z, Deng W, et al. Expression of angiogenic factors in hepatocellular carcinoma after transcatheter arterial
chemoembolization. J Huazhong Univ Sci Technolog Med Sci 2003;23:280-2.
137. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, et al. TTranscatheter arterial chemoembolization (TACE) in hepatocellular
carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008;103:914-21.
138. Xuan ZD, Zhou L, Wang Y, Zheng X. Prognostic value of the combination of serum levels of vascular endothelial growth factor,
C-reactive protein and contrast-enhanced ultrasound in patients with primary liver cancer who underwent transcatheter arterial
chemoembolization. Expert Rev Anticancer Ther 2017;17:1169-78.
139. Katyal S, Oliver JH, Peterson MS, Chang PJ, Baron RL, et al. Prognostic significance of arterial phase CT for prediction of response
to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: a retrospective analysis. Am J Roentgenol
2000;175:1665-72.
140. Lee YK, Kim SU, Kim DY, Ahn SH, Lee KH, et al. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in
patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer 2013;13:5.
141. Kim BK, Ahn SH, Seong JS, Park JY, Kim DY, et al. Early α-fetoprotein response as a predictor for clinical outcome after localized
concurrent chemoradiotherapy for advanced hepatocellular carcinoma. Liver Int 2011;31:369-76.
142. Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, et al. Alpha-fetoprotein response after locoregional therapy for
hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 2009;27:5734-42.
143. Yang Z, Zhang J, Lu Y, Xu Q, Tang B, et al. Aspartate aminotransferase-lymphocyte ratio index and systemic immune-inflammation index
predict overall survival in HBV-related hepatocellular carcinoma patients after transcatheter arterial chemoembolizations. Oncotarget
2015;6:43090-8.
144. Shen Y, Wang H, Li W, Chen J. Prognostic significance of the CRP/Alb and neutrophil to lymphocyte ratios in hepatocellular carcinoma
patients undergoing TACE and RFA. J Clin Lab Anal 2019;33:e22999.
145. Cai XR, Chen ZH, Liu MM, Lin JX, Zhang XP, et al. Modified CLIP score with the albumin-bilirubin grade retains prognostic value in
HBV-related hepatocellular carcinoma patients treated with trans-catheter arterial chemoembolization therapy. J Cancer 2018;9:2380-8.
146. Kim JH, Sinn DH, Lee JH, Hyun D, Cho SK, et al. Novel albumin–bilirubin grade-based risk prediction model for patients with
hepatocellular carcinoma undergoing chemoembolization. Dig Dis Sci 2018;63:1062-71.
147. Chung GE, Kim W, Lee JH, Kim YJ, Yoon JH, et al. Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B
virus-related hepatocellular carcinoma after ablation therapy. J Gastroenterol Hepatol 2011;26:1638-45.
148. Sohn W, Paik YH, Lee MW, Rhim H, Lim HK, et al. Predisposing factors for recurrence of HBV-related small hepatocellular carcinoma
after percutaneous radiofrequency ablation. Scand J Gastroenterol 2014;49:373-80.
149. Kim SS, Nam JS, Cho HJ, Won JH, Kim JW, et al. Plasma micoRNA-122 as a predictive marker for treatment response following
transarterial chemoembolization in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2017;32:199-207.
150. Cui L, Hu Y, Bai B, Zhang S. Serum miR-335 level is associated with the treatment response to trans-arterial chemoembolization and
prognosis in patients with hepatocellular carcinoma. Cell Physiol Biochem 2015;37:276-83.
151. Lu YL, Yao JG, Huang XY, Wang C, Wu XM, et al. Prognostic significance of miR-1268a expression and its beneficial effects for post-
operative adjuvant transarterial chemoembolization in hepatocellular carcinoma. Sci Rep 2016;6:36104.
152. Ali HEA, Emam AA, Zeeneldin AA, Srour R, Tabashy R, et al. Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify
hepatocellular carcinoma patients according to their response to transarterial chemoembolization. Clin Biochem 2019;65:45-52.
153. Gao Y, Zheng DY, Cui Z, Ma Y, Liu YZ, et al. Predictive value of quantitative contrast-enhanced ultrasound in hepatocellular carcinoma
recurrence after ablation. World J Gastroenterol 2015;21:10418-26.
154. Kim SH, Lee WJ, Lim HK, Lim JH. Prediction of viable tumor in hepatocellular carcinoma treated with transcatheter arterial
chemoembolization: usefulness of attenuation value measurement at quadruple-phase helical computed tomography. J Comput Assist
Tomogr 2007;31:198-203.
155. Kokabi N, Ludwig JM, Camacho JC, Xing M, Mittal PK, et al. Baseline and early MR apparent diffusion coefficient quantification as a
predictor of response of unresectable hepatocellular carcinoma to doxorubicin drug-eluting bead chemoembolization. J Vasc Interv Radiol
2015;26:1777-86.
156. Kim HC, Kim AY, Han JK, Chung JW, Lee JY, et al. Hepatic arterial and portal venous phase helical CT in patients treated with
transcatheter arterial chemoembolization for hepatocellular carcinoma: added value of unenhanced images. Radiology 2002;225:773-80.
157. Ebied OM, Federle MP, Carr BI, Pealer KM, Li W, et al. Evaluation of responses to chemoembolization in patients with unresectable
hepatocellular carcinoma. Cancer 2003;97:1042-50.
158. Park HJ, Kim JH, Choi SY, Lee ES, Park SJ, et al. Prediction of therapeutic response of hepatocellular carcinoma to transcatheter arterial
chemoembolization based on pretherapeutic dynamic CT and textural findings. Am J Roentgenol 2017;209:W211-20.
159. Maesaka K, Sakamori R, Yamada R, Tahata Y, Urabe A, et al. Hypovascular hepatic nodules as a predictive factor for transcatheter
arterial chemoembolization refractoriness in hepatocellular carcinoma. Hepatol Res 2020;50:365-73.
160. Choi SJ, Kim J, Seo J, Kim HS, Lee JM, et al. Parametric response mapping of dynamic CT as an imaging biomarker to distinguish
viability of hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Abdom Imaging 2014;39:518-25.
161. Huppertz A, Haralda S, Kraus A, Zech CJ, Scheidler J, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging:
correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005;234:468-78.
162. Ishimaru H, Nakashima K, Sakugawa T, Sakamoto A, Matsuoka Y, et al. Local recurrence after chemoembolization of hepatocellular
carcinoma: uptake of gadoxetic acid as a new prognostic factor. Am J Roentgenol 2014;202:744-51.
163. Ou HY, Cheng YF, Chuang YH, Hsu HW, Chen CL, et al. Quantification of functional MR predicts early response in post-doxorubicin